1 |
Choi WJ, Ivanics T, Gravely A, Gallinger S, Sapisochin G, O'Kane GM. Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring. Ann Surg Oncol 2023. [PMID: 36808320 DOI: 10.1245/s10434-023-13126-x] [Reference Citation Analysis]
|
2 |
Hofste LSM, Geerlings MJ, von Rhein D, Rütten H, Westenberg AH, Weiss MM, Gilissen C, Hofste T, van der Post RS, Klarenbeek BR, de Wilt JHW, Ligtenberg MJL; Libic2 collaborators group. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer. Eur J Surg Oncol 2023:S0748-7983(23)00093-8. [PMID: 36740555 DOI: 10.1016/j.ejso.2023.01.026] [Reference Citation Analysis]
|
3 |
Chan HT, Nagayama S, Otaki M, Chin YM, Fukunaga Y, Ueno M, Nakamura Y, Low SK. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients. Front Oncol 2022;12:1055968. [PMID: 36776372 DOI: 10.3389/fonc.2022.1055968] [Reference Citation Analysis]
|
4 |
Dayyani F, Smith BR, Nguyen NT, Daly S, Hinojosa MW, Seyedin SN, Kuo J, Samarasena JB, Lee JG, Taylor TH, Cho MT, Senthil M. A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future Oncol 2022. [PMID: 35603628 DOI: 10.2217/fon-2022-0285] [Reference Citation Analysis]
|